Related Experiment Video
Updated: May 5, 2026

Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
The future of antiplatelet therapy in cardiovascular disease
1Department of Pharmacology, Catholic University School of Medicine, Rome, Italy. carlo.patrono@rm.unicatt.it
Abstract:
Mechanisms of platelet inhibition are reviewed with emphasis on the pharmacokinetic and pharmacodynamic determinants of clinical efficacy and safety of antiplatelet drugs. Current developments in antiplatelet therapy are discussed in relation to both primary and secondary prevention of atherothrombotic complications. Interindividual variability in response to antiplatelet agents and new drug targets are outlined within the context of optimizing the balance between the cardiovascular benefits and bleeding risks of antiplatelet therapy. Recent advances in the pharmacogenetics of thienopyridines open the realistic prospect of a personalized choice of the most appropriate antiplatelet agent and tailored dose adjustment for an individual patient.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care
Venous Thrombosis III: Interprofessional Care

